Jennison Associates LLC acquired a new position in AbbVie Inc (NYSE:ABBV) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,126,689 shares of the company’s stock, valued at approximately $544,418,000. Jennison Associates LLC owned 0.38% of AbbVie as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also modified their holdings of the company. BKD Wealth Advisors LLC boosted its position in shares of AbbVie by 7.4% during the second quarter. BKD Wealth Advisors LLC now owns 15,238 shares of the company’s stock worth $1,105,000 after buying an additional 1,051 shares during the period. Baker Boyer National Bank purchased a new position in shares of AbbVie during the second quarter worth $204,000. Capital One National Association boosted its position in shares of AbbVie by 3.4% during the second quarter. Capital One National Association now owns 142,470 shares of the company’s stock worth $10,331,000 after buying an additional 4,685 shares during the period. Deane Retirement Strategies Inc. purchased a new position in shares of AbbVie during the second quarter worth $1,733,000. Finally, Perkins Coie Trust Co boosted its position in shares of AbbVie by 7.1% during the second quarter. Perkins Coie Trust Co now owns 23,955 shares of the company’s stock worth $1,737,000 after buying an additional 1,588 shares during the period. Institutional investors own 69.19% of the company’s stock.
In other news, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total value of $1,657,065.00. Following the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Laura J. Schumacher sold 145,510 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $96.71, for a total value of $14,072,272.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 494,676 shares of company stock worth $47,237,938. Insiders own 0.23% of the company’s stock.
Shares of AbbVie Inc (ABBV) opened at $104.36 on Thursday. The stock has a market capitalization of $163,618.09, a price-to-earnings ratio of 25.39, a PEG ratio of 1.23 and a beta of 1.52. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 52 week low of $59.27 and a 52 week high of $104.84.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.02. The business had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the firm earned $1.21 earnings per share. analysts anticipate that AbbVie Inc will post 5.54 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.71 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a dividend yield of 2.72%. The ex-dividend date is Thursday, January 11th. AbbVie’s dividend payout ratio (DPR) is presently 69.10%.
Several research firms have recently commented on ABBV. Vetr lowered AbbVie from a “strong-buy” rating to a “buy” rating and set a $113.08 price target for the company. in a research report on Monday, January 8th. Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Jefferies Group raised their price target on AbbVie from $115.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, January 4th. BMO Capital Markets set a $84.00 price target on AbbVie and gave the stock a “hold” rating in a research report on Thursday, January 11th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of AbbVie in a research report on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie currently has a consensus rating of “Buy” and a consensus target price of $100.94.
ILLEGAL ACTIVITY NOTICE: “Jennison Associates LLC Acquires Shares of 6,126,689 AbbVie Inc (ABBV)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2018/01/18/jennison-associates-llc-acquires-shares-of-6126689-abbvie-inc-abbv.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.